News ImmuneRegen NewsImmuneRegen BioSciences Meets with the New York State Office of Public SecurityEfficacy of Company's Radilex™ Analyzed as a Universal Protectant Against Terrorist Attacks SCOTTSDALE, Ariz., February 14, 2005 -- ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTC Bulletin Board: IRBO) announced it recently met with the New York State Office of Public/Homeland Security (NYSOPS), the agency responsible for the detection, identification, response, prevention, and recovery from a terrorist act or threat in New York State. The meeting served a twofold purpose: To educate the attending state leaders regarding the efficacy of ImmuneRegen’s proprietary compound Radilex™, and to alert these officials of the compound's availability under Project BioShield's Emergency Use Authorization clause for potential stockpiling as a universal protectant from terrorist attacks. This includes treating acute radiation sickness (ARS) in the event of a nuclear attack and protecting against the effects of chemical warfare agents and biological agents such as anthrax and ricin. The primary focus of the gathering was on the potential efficacy of Radilex™ in treating acute radiation sickness. Radilex directly treats the effects of toxic exposure on living cells by inhibiting cell apoptosis (cell-initiated death process). Currently, Radilex™ is the only drug compound in existence, which has proven a fifty percent (50%) survival rate for subjects exposed to fatal doses of radiation in pre-clinical animal models. Emergency distribution was also a major topic of discussion. Radilex™ requires no prophylactic treatment and is administered through a device similar to an asthma inhaler, which simplifies mass treatment. However, as the majority of damage from radiation exposure occurs within hours, having potentially life-saving drugs such as Radilex™ stockpiled in central locations for immediate distribution after an incident is critical. Michael Wilhelm, ImmuneRegen CEO, and John Fermanis, ImmuneRegen CFO, met with NYSOPS officials in Albany on January 19, 2005. The officials participating in the meeting included: the Director, NYSOPS; the Deputy Director/Chief Counsel, NYSOPS and the Health Policy Advisor, NYSOPS. "While the New York State Office of Public Security has not yet committed to including Radilex™ in the New York emergency stockpile, we are hopeful that after they have concluded their review of our seven completed studies, they will agree that Radilex™ would be a wise investment of the funds allocated to the state by the Federal Government under Homeland Security and Project BioShield," says Michael K. Wilhelm, CEO of ImmuneRegen BioSciences, Inc. In addition, during the final week of January the ImmuneRegen team met with several congressional leaders responsible for legislation relating to Homeland Security. A number of these individuals hold positions on committees involved in national security. ImmuneRegen is currently working with their congressional staff to pursue further advances under Project BioShield. Mr. Wilhelm further clarified the function of these January meetings: "We believe it is vital for the state and federal officials charged with the task of Homeland Security to know that Radilex™ is available for stockpiling and ready to be utilized under the Emergency Use Authorization clause found in Project BioShield." The primary focus of the gathering was on the potential efficacy of Radilex™ in treating acute radiation sickness. Radilex™ directly treats the effects of toxic exposure on living cells by inhibiting cell apoptosis (cell-initiated death process). Currently, Radilex™ is the only drug compound in existence, which has proven a fifty percent (50%) survival rate for subjects exposed to fatal doses of radiation in pre-clinical animal models. About ImmuneRegen BioSciences, Inc.a wholly owned subsidiary of IR BioSciences Holdings, Inc., (OTC BB:IRBS.OB - News) is a development-stage biotechnology company focused on the research, development and licensing of Homspera™ and its derivatives. Homspera is an adult stem cell active compound that in study results has been shown to regenerate and strengthen the immune system and enhance wound healing. Viprovex®, a derivative of Homspera, is being developed for potential use against infectious diseases as a stand-alone or combination therapy and as a vaccine adjuvant. To advance its mission, the Scottsdale, Arizona based company has forged numerous study partnerships with industry and academic leaders, including Celgene Cellular Therapeutics, HemoGenix, Lovelace Respiratory Research Institute and Virion Systems. For more information, please visit www.immuneregen.com. Statements about ImmuneRegen's future expectations, including statements about the potential use and scientific results for ImmuneRegen's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. ImmuneRegen intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with ImmuneRegen's business, are subject to various risks and uncertainties. ImmuneRegen's actual results could differ materially from expected results as a result of a number of factors, including the uncertainties inherent in research and development collaborations, pre-clinical and clinical trials and product development programs (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials), the evaluation of potential opportunities, the level of corporate expenditures and monies available for further studies, capital market conditions, and others set forth in ImmuneRegen's periodic report on Form 10-Q for the three months ended June 30, 2008 and on Form 10-KSB for the year ended December 31, 2007 as filed with the Securities and Exchange Commission. There are no guarantees that any of ImmuneRegen's proposed products will prove to be commercially successful. ImmuneRegen undertakes no duty to update forward-looking statements. Contact: or
### Copyright © 2003-2008, ImmuneRegen Biosciences, Inc. All rights reserved. |
|